Like many in Silicon Valley, technology entrepreneur Bryan Johnson sees a future in which intelligent machines can do things like drive cars on their own and anticipate our needs before we ask. What’s uncommon is how Johnson wants to respond: find a way to supercharge the human brain so that we can keep up with the machines.
Healthcare IT News traveled to Epic’s Verona, Wisconsin, campus and met with the company’s elusive founder, as well as with Epic Vice President Peter DeVault. The two talked a lot about interoperability – but perhaps not enough to quell critics.
At the end of every year, Edge reaches out to the smartest people on the planet and asks them a single question in an attempt to find the ideas and concepts that are changing the world of science. This year’s two-part question was: “What do you consider the most interesting recent [scientific] news? What makes it important?”
Not surprisingly, this year’s set of 197 responses converged around a few key themes – the human brain, the human genome, space exploration and artificial intelligence. Based on these responses, here are 10 of the edgiest innovation buzzwords that have the greatest potential to change the trajectory of innovation in 2016.
On a campus famed for its breakthroughs in biotechnology, engineering and agriculture, a much smaller department is exerting an outsized effect on the Wisconsin economy – and beyond.
The UW-Madison Department of Computer Sciences, which has been in the forefront of computational innovation since the dawn of the Internet, is poised to build upon its quiet national reputation while expanding its ties to companies close to home.
The next time you stop by your local supermarket, take a long, hard look at the yellow bananas in the produce section. That’s because bananas might be extinct within just a few years, say Dutch researchers, and that could open the door for synthetic biologists to come up with a new, synthetically modified banana to replace the yellow Cavendish banana we’ve come to know and love.
This new, synthetically modified banana would look like a real banana and taste like a real banana and it would have almost exactly the same DNA as a real banana — except that it would be engineered in a bio-foundry by a team of technologists. This genetically engineered banana would have some of its genetic material designed or edited to behave differently than it does now.
More than 200 years ago, British economist Thomas Robert Malthus famously suggested that the earth would run out of food resources to feed a burgeoning global population. Now, thanks to advances in synthetic biology and genetic engineering, we could soon be talking about exponential increases in the earth’s food supply rather than the “arithmetical” increases predicted by Malthus.
Silicon Valley efforts in the biology and health domains have recently seen increased public interest because of the questions around the legitimacy of Theranos’ technology and medical claims and the recent FDA approvals for a number of 23andMe’s genetic screens.
These data points are just two of the most visible examples of a broad ecosystem of companies and startups in Silicon Valley working on biological problems. This early “biohacking” ecosystem has a number of parallels with the personal computer (PC) ecosystem in the 1970s and 1980s.
Let’s face it: If we knew precisely why stock markets surge up, down and sideways at the drop of a hat, we would all be a lot richer.
Such is the inexact science of trying to make sense of why the stock of Exact Sciences, a Madison-based cancer diagnostics company, took a nosedive Tuesday over a draft report from an independent healthcare review panel.
Stockholders and others who follow the company may want to take a deep breath before concluding the stock plunge is anything more than a speed bump in what has been an otherwise fast and smooth road for Exact Sciences.
Both public sector agencies and private sector investors are pouring new money into the synthetic biology space, and that’s leading to a situation where we can expect a burst of new innovations impacting fields as diverse as agriculture, energy and health. According to the latest “U.S. Trends in Synthetic Biology Research Funding” report from the Wilson Center’s Synthetic Biology Project in Washington, D.C., the U.S. government funded more than $820 million in synthetic biology research programs in the period from 2008-2014.
Shares of Exact Sciences Corp. plunged Tuesday morning after the U.S. Preventive Services Task Forceissued a preliminary recommendation, saying it considers the company’s non-invasive colon cancer test as an “alternative test.”
The Madison company’s stock dropped more than 40% in morning trading. The shares, which closed at $18.53 on Monday, dipped nearly as low as $10 Tuesday morning.